Dermatitis Drugs Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032

Growth Factors of Dermatitis Drugs Market

The dermatitis drugs market size was valued at USD 6097.4 million in 2018, and the market is now projected tgrow USD 20919.4 million in 2032, exhibiting a CAGR of 8.9% during the forecast period of 2019-2032.

The dermatitis drugs market faced some changes due tthe COVID-19 pandemic, with the restrictions that affected diagnostics and treatment of patients. Closures occurred in many dermatology clinics due twhich patients have access tspecialized care and treatment only in the short term. The addition of new dermatitis drugs was another area which suffered from delayed clinical trials, which delayed the introduction of innovative therapies. However, the use of telemedicine and remote consultations was able tserve some as an answer tsustaining this paradigm. Over time the market is gradually regrowing and has been fueled by the growing awareness of more intricate dermatological procedures amongst patients.

One major factor that can be considered in the dermatitis drugs market today is the high fragmentation of the market hence; there are several manufacturers whdeal with the production of generic drugs. Dupilumab sold under the brand name Dupixent by Regeneron Pharmaceuticals and Sanofi has been tremendously transformed dermatitis treatment due tefficacy as well as emerging approval. This interleukin-4 inhibitor has now emerged as one of the most common treatments for curing dermatitis symptoms. Overall, Dupixent for the year 2018 touched about US$ 922 million in sales. The outcome of the drug points tthe progression towards more effective therapies in dermatitis market.

Demand for dermatitis drugs is growing because of the progress in biologics and other targeted agents like Dupixent. Twmajor trends are discernible at the present, one being that of a growing interest at the field of pharmacokinetics personalized medicine the second being that connected with the appearance of biologic products that target certain immune response. There is a growing interest in skin diseases and their advancement’s effects on the quality of life, which creates the need for efficient treatment. The market is alsexperiencing an increase in the use of topical corticosteroids and other improved formulations of recently developed molecules. Furthermore, telemedicine, and other digital solutions are improving outcomes of patient monitoring and disease management.

Comprehensive Analysis of Dermatitis Drugs Market

The dermatitis drugs market growth is rising at an exponential rate due tits market segmentation. This market expansion rightly presents a detailed local analysis based on the forces such as supply and demand which define the industry. These segmentations are methodically segregated by drug class, by disease indication, by distribution channel, and by geography. By drug class include calcineurin inhibitors, PDE4 inhibitors, corticosteroids, biologics, and others. By disease indication include atopic dermatitis, contact dermatitis and others. By distribution channel include hospital pharmacy, retail pharmacy, and online pharmacy. By geography include North America, Europe, Asia Pacific, and rest of world.

The North America region lead the dermatitis drugs market share by benefitting a market size of USD 3149.7 million in 2018 due tits advanced healthcare infrastructure.

The top players have a significant responsibility in the healthcare industry for confirming industrial prospectus growth and determining the market trends. These players include, Valeant Pharmaceuticals, Astellas Pharma US, Inc., Pfizer, Inc., Mylan, Bayer AG, Allergan, LEO Pharma, Regeneron Pharmaceuticals, Inc., and Anacor Pharmaceuticals, Inc. these market players provide a level-playing competitive landscape.

In March 2020, Valeant Pharmaceuticals (now Bausch Health Companies) launched a new topical treatment for eczema, expanding its dermatology portfolio.

Segmentation Table

ATTRIBUTE DETAILS

Drug Class

Calcineurin Inhibitors

PDE4 Inhibitors

Corticosteroids

Biologics

Others

By Disease Indication

Atopic Dermatitis

Contact Dermatitis

Others

By Distribution Channel

Hospital Pharmacy

Retail Pharmacy

Online Pharmacy

By Geography

North America (USA and Canada)

Europe (UK, Germany, France, Italy, Spain, Scandinavia, and Rest of Europe)

Asia Pacific (Japan, China, India, Australia, Southeast Asia, and Rest of Asia Pacific)

Rest of World